Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Array Biopharma Inc (ARRY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,326,023
  • Shares Outstanding, K 213,070
  • Annual Sales, $ 173,770 K
  • Annual Income, $ -147,350 K
  • 36-Month Beta 1.11
  • Price/Sales 18.70
  • Price/Cash Flow N/A
  • Price/Book 14.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.16
  • Number of Estimates 7
  • High Estimate -0.08
  • Low Estimate -0.26
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.66 +14.28%
on 10/25/18
17.47 -10.65%
on 11/08/18
+0.46 (+3.04%)
since 10/19/18
3-Month
12.56 +24.28%
on 10/11/18
17.47 -10.65%
on 11/08/18
+1.75 (+12.63%)
since 08/21/18
52-Week
10.36 +50.68%
on 12/06/17
20.21 -22.76%
on 06/21/18
+4.40 (+39.25%)
since 11/21/17

Most Recent Stories

More News
Radius Health In has the Best Relative Performance in the Biotechnology Industry (RDUS , SGMO , ARRY , ARWR, FLXN )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SGMO : 11.12 (+5.40%)
ARWR : 12.95 (+5.28%)
ARRY : 15.61 (+2.36%)
RDUS : 15.76 (+1.68%)
Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference....

ARRY : 15.61 (+2.36%)
Analysis: Positioning to Benefit within Array BioPharma, SPX FLOW, Holly Energy Partners, Electro Scientific Industries, Leggett & Platt, and CBL & Associates Properties -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Array BioPharma Inc. (NASDAQ:ARRY),...

SCND : 3.3600 (-11.58%)
HEP : 28.57 (+2.18%)
ESIO : 28.84 (+0.10%)
ARRY : 15.61 (+2.36%)
CBL : 2.82 (+5.22%)
FLOW : 35.87 (+5.19%)
FLOW : 35.87 (+5.19%)
LEG : 37.79 (+0.69%)
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies

Financialnewsmedia.com News Commentary

KIN : 12.83 (+1.50%)
ARRY : 15.61 (+2.36%)
SBBP : 5.23 (+2.55%)
PFE : 43.10 (-0.99%)
MBRX : 1.35 (-1.46%)
Array BioPharma (ARRY) Reports Q1 Loss, Tops Revenue Estimates

Array BioPharma (ARRY) delivered earnings and revenue surprises of 42.86% and 59.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ARRY : 15.61 (+2.36%)
Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019

Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its first quarter of fiscal 2019 and provided an update on the progress of its key commercial products and clinical development programs.

ARRY : 15.61 (+2.36%)
Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018

Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, October 30, 2018. Ron Squarer, Chief...

ARRY : 15.61 (+2.36%)
Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release

Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARRY : 15.61 (+2.36%)
SmarTrend Watching for Potential Pullback in Shares of Array Biopharma After 4.52% Gain

Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $14.83 to a high of $15.96. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of...

ARRY : 15.61 (+2.36%)
Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference

Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 2018 Cantor Global Healthcare Conference in New York. The public is welcome to participate...

ARRY : 15.61 (+2.36%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade ARRY with:

Business Summary

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory...

See More

Key Turning Points

2nd Resistance Point 16.26
1st Resistance Point 15.93
Last Price 15.61
1st Support Level 15.18
2nd Support Level 14.76

See More

52-Week High 20.21
Fibonacci 61.8% 16.45
Last Price 15.61
Fibonacci 50% 15.28
Fibonacci 38.2% 14.12
52-Week Low 10.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar